QUICK ANSWER
P-tau181 (phosphorylated tau at threonine 181) is a blood or CSF biomarker that reflects Alzheimer's disease-related brain changes — specifically the accumulation of amyloid plaques and tau tangles.
Reference ranges vary significantly by assay and platform:
| Platform | Commonly reported negative threshold | Commonly reported positive threshold |
|---|---|---|
| Lumipulse (Fujirebio) | ≤ ~0.95 pg/mL | ≥ ~1.3–1.5 pg/mL |
| Simoa (ALZpath / Quanterix) | ≤ ~2.0–2.25 pg/mL | ≥ ~2.5–3.0 pg/mL |
| Quest AD-Detect (T -- P-Tau181) | Consult report cutoff | Consult report cutoff |
These numbers are approximations from published validation studies. Always use the reference range and cutoff printed on your own lab report — platforms are not interchangeable.
Key takeaway: A high p-tau181 increases the likelihood of Alzheimer's-type pathology. A normal p-tau181 makes it less likely. Like all AD blood biomarkers, it is a diagnostic aid — not a standalone diagnosis.
WHAT IS P-TAU181?
Tau is a protein that stabilizes structures inside brain cells. In Alzheimer's disease, tau becomes abnormally phosphorylated — chemically modified at specific sites — causing it to detach from its normal function, aggregate into tangles, and damage neurons.
Phosphorylated tau-181 refers to tau that has been modified specifically at threonine 181, one of the earliest and most studied phosphorylation sites in Alzheimer's disease. As this process occurs in the brain, p-tau181 leaks into the bloodstream and cerebrospinal fluid (CSF), where it can be measured.
P-tau181 in plasma vs CSF:
- Plasma (blood) p-tau181 is a newer, less invasive measurement. It requires only a blood draw and is increasingly available through commercial labs including Quest Diagnostics (AD-Detect panel) and labs using Lumipulse or Simoa platforms.
- CSF p-tau181 has a longer research history and is measured during a lumbar puncture. It remains a gold-standard confirmatory test but requires a more invasive procedure.
WHAT DOES HIGH P-TAU181 MEAN?
High p-tau181 (above the positive cutoff on your report) means Alzheimer's-related amyloid and tau pathology is likely present in the brain. The higher the value above the threshold, the stronger the signal.
Clinically, a high result:
- Supports — but does not confirm — a clinical diagnosis of Alzheimer's disease
- May prompt your clinician to order confirmatory testing (amyloid PET scan or CSF biomarkers)
- May support eligibility evaluation for Alzheimer's disease-modifying treatments
- Helps differentiate Alzheimer's disease from other forms of dementia when the diagnosis is unclear
What a high result does not mean:
- It is not a standalone diagnosis of Alzheimer's disease
- It does not predict the rate of cognitive decline
- It does not mean dementia is imminent — pathology may be present years before significant symptoms
WHAT DOES LOW P-TAU181 MEAN?
Low p-tau181 (below the negative cutoff) makes Alzheimer's-type pathology less likely at the time of testing. This is a reassuring finding in a patient being evaluated for possible Alzheimer's disease.
A negative result may redirect evaluation toward other causes of cognitive symptoms — vascular dementia, Lewy body dementia, depression, metabolic conditions, or medication effects.
A negative result does not completely exclude Alzheimer's disease, particularly in early-stage or atypical presentations.
HOW TO READ YOUR RESULT: SPECIFIC NUMBERS
If your result is from the Lumipulse platform (typical range ~0.3–3.0 pg/mL):
| P-tau181 result (pg/mL) | Typical interpretation |
|---|---|
| Under 0.8 | Clearly negative — AD pathology unlikely |
| 0.8–1.0 | Near the negative threshold — typically negative |
| 1.0–1.3 | Indeterminate / borderline — further evaluation often recommended |
| 1.3–1.5 | Near the positive threshold — borderline positive |
| Above 1.5 | Clearly elevated — AD pathology likely |
If your result is from the Simoa platform (ALZpath, Quanterix; typical range ~0.5–10+ pg/mL):
| P-tau181 result (pg/mL) | Typical interpretation |
|---|---|
| Under 1.8 | Typically negative |
| 1.8–2.5 | Borderline / indeterminate |
| Above 2.5 | Elevated — consistent with AD pathology |
If your report says "T -- P-Tau181" or "T--P-Tau181": This is the Quest AD-Detect report format for plasma p-tau181. Use the reference range printed on your Quest report — Quest uses their own validated cutoffs which may differ from the approximations above.
P-TAU181 VS P-TAU217: WHAT IS THE DIFFERENCE?
These are two different phosphorylation sites on the same tau protein. Both reflect Alzheimer's disease pathology, but they differ in important ways:
| Feature | P-tau181 | P-tau217 |
|---|---|---|
| Phosphorylation site | Threonine 181 | Threonine 217 |
| Clinical availability | Widely available — Quest, LabCorp, Lumipulse labs | Growing availability — Lumipulse (FDA-cleared), specialty labs |
| Diagnostic accuracy | High (AUC ~0.85–0.92) | Generally higher (AUC ~0.90–0.96) |
| Research history | Longer — more published validation data | Newer — but rapidly accumulating evidence |
| FDA clearance | Not cleared as a standalone test | Lumipulse p-tau217/Aβ42 ratio cleared May 16, 2025 |
| Report format | Often pg/mL (absolute) | Often pg/mL (absolute) or ratio |
The practical difference: P-tau217 tends to rise earlier and more steeply in Alzheimer's disease and generally shows higher diagnostic accuracy in head-to-head comparisons. However, p-tau181 is more widely available, has a longer validation history, and remains clinically useful — particularly when p-tau217 is not available or when used as part of a multimarker panel (e.g., with Aβ42/40 ratio).
WHAT IS THE QUEST AD-DETECT P-TAU181 TEST?
Quest Diagnostics offers plasma p-tau181 as part of its AD-Detect panel. On Quest reports, plasma p-tau181 appears as "T -- P-Tau181" or similar formatting. The test uses a Simoa-based immunoassay and reports in pg/mL.
The AD-Detect panel typically includes:
- Plasma p-tau181 (T -- P-Tau181)
- Plasma Aβ42/40 ratio
- Sometimes additional tau or amyloid markers (some panel versions may include p-tau217)
Quest provides its own reference ranges and cutoffs on the report. Do not apply cutoffs from Lumipulse or ALZpath validation studies to Quest AD-Detect results.
CAN P-TAU181 BE ELEVATED BEFORE SYMPTOMS APPEAR?
Yes. Like p-tau217, plasma p-tau181 can become elevated years before cognitive symptoms become obvious. The biomarker reflects the underlying biological process — amyloid accumulation and tau phosphorylation — not the current severity of memory loss.
This means a person with elevated p-tau181 may currently have:
- Mild cognitive impairment (MCI)
- Subjective memory concerns without objective deficits
- No obvious symptoms at all
An elevated result in the absence of clear dementia symptoms does not mean dementia is imminent. It indicates the pathological process is underway and warrants clinical follow-up.
WHEN TO FOLLOW UP
Discuss your p-tau181 result with a clinician if:
- Your result is above the positive cutoff on your report — confirmatory testing (amyloid PET or CSF) may be recommended
- Your result is borderline — repeat testing, additional biomarkers (Aβ42/40 ratio, p-tau217), or imaging may be ordered
- Your result is negative but symptoms are progressing — other causes of cognitive change need investigation
- You are considering or already on Alzheimer's disease-modifying therapy
BOTTOM LINE
Bottom line: P-tau181 is an established blood and CSF biomarker for Alzheimer's-type pathology. Reference ranges vary significantly by platform — Lumipulse, Simoa, and Quest AD-Detect all use different cutoffs that cannot be compared directly. P-tau217 generally shows higher diagnostic accuracy but p-tau181 remains widely useful, especially where p-tau217 is unavailable. A high result increases the likelihood of AD pathology; a normal result makes it less likely. Neither is a standalone diagnosis.
p-tau181
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
Frequently Asked Questions
Can kidney disease affect p-tau181 levels?
What if my p-tau181 is high but my p-tau217 is intermediate?
What is the normal range for p-tau181?
What does it mean when my result says "T -- P-Tau181"?
What does high p-tau181 mean?
How does p-tau181 compare to p-tau217?
Can p-tau181 be elevated without symptoms?
Do I still need a PET scan or lumbar puncture after a p-tau181 result?
Is p-tau181 the same as total tau?
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.
-
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
-
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
-
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
-
Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform